(firstQuint)Anti-Inflammatory Agent in Sinusitis.

 This is a Phase 2a, single-center, randomized, placebo-controlled, double-blind study that includes 12 weeks of treatment with experimental drug anti-inflammatory agent or placebo TID administered orally.

 All subjects will be 18 years, have sinusitis with persistent symptoms despite standard of care treatment, and have failed a course of steroids in the past.

.

 Anti-Inflammatory Agent in Sinusitis@highlight

To evaluate the efficacy of an anti-inflammatory agent compared with placebo in relieving signs and symptoms of disease in patients with sinusitis.

